source
- Novo to pay up to $2.6 billion for rights to Hengrui’s experimental weekly obesity pillNovo Pharmaceuticals has signed a licensing agreement with China's Hengrui Pharma to acquire an experimental oral weight‑loss drug that is administered once a week. Under the deal, Novo could pay…
- ai3Bio raises $48 million to develop T-helper cell-targeted immune-reset therapiesai3Bio, a new biotech startup formed from Corner Therapeutics and Novasenta, announced it has secured $48 million in an early-stage venture capital round. The company aims to create treatments for…